Skip to content
Etodolac
Lodine (etodolac) is a small molecule pharmaceutical. Etodolac was first approved as Lodine on 1991-01-31. It is used to treat osteoarthritis, pain, and rheumatoid arthritis in the USA. The pharmaceutical is active against prostaglandin G/H synthase 2.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
skin and connective tissue diseasesD017437
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Etodolac
Tradename
Company
Number
Date
Products
LODINEWYETH PHARMS INCN-018922 DISCN1991-01-31
4 products, RLD
LODINE XLWYETH PHARMS INCN-020584 DISCN1996-10-25
3 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
antiseptic povidone-lodine prep padOTC monograph not final2022-09-29
etodolacANDA2023-05-25
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
osteoarthritisEFO_0002506D010003M15-M19
painEFO_0003843D010146R52
rheumatoid arthritisEFO_0000685D001172M06.9
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
M01: Antiinflammatory and antirheumatic products
M01A: Antiinflammatory and antirheumatic products, non-steroids
M01AB: Acetic acid derivatives and related substances
M01AB08: Etodolac
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pyogenic granulomaD017789K13.411
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameETODOLAC
INNetodolac
Description
Etodolac is a monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active. It has a role as a non-steroidal anti-inflammatory drug, a cyclooxygenase 2 inhibitor, a non-narcotic analgesic and an antipyretic. It is a monocarboxylic acid and an organic heterotricyclic compound.
Classification
Small molecule
Drug classanti-inflammatory agents (acetic acid derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
Identifiers
PDB
CAS-ID41340-25-4
RxCUI
ChEMBL IDCHEMBL622
ChEBI ID4909
PubChem CID3308
DrugBankDB00749
UNII ID2M36281008 (ChemIDplus, GSRS)
Target
Agency Approved
PTGS2
PTGS2
Organism
Homo sapiens
Gene name
PTGS2
Gene synonyms
COX2
NCBI Gene ID
Protein name
prostaglandin G/H synthase 2
Protein synonyms
COX-2, cyclooxygenase 2, cyclooxygenase 2b, Cyclooxygenase-2, PGH synthase 2, PGHS-2, PHS II, Prostaglandin H2 synthase 2, Prostaglandin-endoperoxide synthase 2, prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)
Uniprot ID
Mouse ortholog
Ptgs2 (19225)
prostaglandin G/H synthase 2 (Q543K3)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,134 documents
View more details
Safety
Black-box Warning
Black-box warning for: Etodolac
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
13 adverse events reported
View more details